Selected for Global Hypergrowth Tokyo Startup Program

Auxilart Inc. (Headquarters: Chuo-ku, Tokyo, CEO: Junu Kim) has been selected for the prestigious Global Hypergrowth Tokyo program, designed to accelerate the growth of Japanese startups with global expansion potential.

This program is supported by JETRO (Japan External Trade Organization) and aims to provide startups with the resources, mentorship, and global network necessary to succeed in international markets. Through this program, Auxilart will benefit from expert guidance and opportunities to connect with investors and corporate partners to propel its global expansion.

For more details, click here.

About Global Hypergrowth Tokyo

Global Hypergrowth Tokyo is a startup accelerator program that targets high-growth Japanese startups with the ambition to expand into global markets. The program provides selected startups with specialized mentorship, funding support, and networking opportunities with global investors, entrepreneurs, and industry leaders. The goal of the program is to help startups scale their business internationally and become global leaders in their fields.

About Startup Genome

Startup Genome is a leading global innovation ecosystem development organization that partners with over 160 economic and innovation agencies, public and private institutions across more than 55 countries. The organization works to accelerate startup success and ecosystem growth, ensuring that every city and country can fairly benefit from the new economy. Startup Genome’s evidence-based ecosystem research, advisory services, and scale-up programs are grounded in global experience, utilizing the world’s largest AI-curated startup database and over a decade of primary research.

Startup Genome Japan is a wholly-owned subsidiary of Startup Genome.

About Auxilart

Auxilart Inc. provides advanced digital simulation solutions based on mechanistic models developed at the University of Tokyo, where the technology has been developed over a decade.

Our Mechanistic model-based simulation technology enables high-precision simulations with minimal data, using only 1% of the data typically required by AI-based methods. By replacing extensive physical experiments with digital simulations, we achieve up to 90% reduction in both cost and time while enhancing productivity.

Founded in 2023, Auxilart has already provided its solutions to Boehringer Ingelheim and major Japanese pharmaceutical companies.

For more information, visit Auxilart's Website.

Media Contact

Auxilart Inc.
Established: July 19, 2023
CEO: Junu Kim
Headquarters: 6F, 1-12-4 Ginza, Chuo-ku, Tokyo, Japan

Contact Person: Kay (Keisuke) Okita
Email: information@auxilart.com